Burden of breast cancer with brain metastasis: a French national hospital database analysis.
作者： L. Benjamin , F.-E. Cotté , F. Mercier , A. Vainchtock , G. Vidal-Trécan
DOI: 10.3111/13696998.2012.662924
关键词:
摘要: AbstractObjective:Incidence of breast cancer with brain metastases (BCBM) is increasing, especially among patients over-expressing HER2. Epidemiology on this sub-type scarce, since registries carry no information the HER2 status. A retrospective database analysis was conducted to estimate burden BCBM, HER2-positive in a secondary objective.Methods:Patients new diagnosis BCBM carried out between January and December 2008 were identified from national hospital using International Disease Classification. Patients receiving targeted anti-HER2 therapy pharmacy database. Hospital claims linked patients. Data hospitalizations extracted describe treatment patterns healthcare costs during 1-year follow-up. Predictors cost analyzed through multi-linear regression analysis.Results:Two thousand ninety-nin...
informahealthcare.com参考文章(32)
E. Pez, A.-S. Gauchez, R. Payan, M. Mousseau, Recherche des métastases cérébrales dans les cancers du sein métastatiques traités par Herceptin® : une place pour la biologie ? Immuno-analyse & Biologie Specialisee. ,vol. 22, pp. 151- 155 ,(2007) , 10.1016/J.IMMBIO.2007.01.003
Nancy U. Lin, Jennifer R. Bellon, Eric P. Winer, CNS Metastases in Breast Cancer Journal of Clinical Oncology. ,vol. 22, pp. 3608- 3617 ,(2004) , 10.1200/JCO.2004.01.175
Raffaele Addeo, Carmine De Rosa, Vincenzo Faiola, Luigi Leo, Gregorio Cennamo, Liliana Montella, Rosario Guarrasi, Bruno Vincenzi, Michele Caraglia, Salvatore Del Prete, Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases Cancer. ,vol. 113, pp. 2524- 2531 ,(2008) , 10.1002/CNCR.23859
Katri Köninki, Minna Tanner, Anssi Auvinen, Jorma Isola, HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005. Breast Cancer Research. ,vol. 11, pp. 1- 6 ,(2009) , 10.1186/BCR2322
R. J. Halbert, Carol Zaher, Sally Wade, Jennifer Malin, Grant D. Lawless, Robert W. Dubois, Outpatient cancer drug costs: Changes, drivers, and the future Cancer. ,vol. 94, pp. 1142- 1150 ,(2002) , 10.1002/CNCR.10347
Alicia Tosoni, Enrico Franceschi, Alba A. Brandes, Chemotherapy in breast cancer patients with brain metastases: Have new chemotherapic agents changed the clinical outcome? Critical Reviews in Oncology Hematology. ,vol. 68, pp. 212- 221 ,(2008) , 10.1016/J.CRITREVONC.2008.04.004
Ian Smith, Marion Procter, Richard D Gelber, Sébastien Guillaume, Andrea Feyereislova, Mitch Dowsett, Aron Goldhirsch, Michael Untch, Gabriella Mariani, Jose Baselga, Manfred Kaufmann, David Cameron, Richard Bell, Jonas Bergh, Robert Coleman, Andrew Wardley, Nadia Harbeck, Roberto I Lopez, Peter Mallmann, Karen Gelmon, Nicholas Wilcken, Erik Wist, Pedro Sánchez Rovira, Martine J Piccart-Gebhart, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial The Lancet. ,vol. 369, pp. 29- 36 ,(2007) , 10.1016/S0140-6736(07)60028-2
Laure Benjamin, François-Emery Cotté, Caroline Philippe, Florence Mercier, Thomas Bachelot, Gwenaëlle Vidal-Trécan, Physicians' preferences for prescribing oral and intravenous anticancer drugs: a Discrete Choice Experiment. European Journal of Cancer. ,vol. 48, pp. 912- 920 ,(2012) , 10.1016/J.EJCA.2011.09.019
Elise M. Pelletier, Boyung Shim, Seth Goodman, Mayur M. Amonkar, Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis. Breast Cancer Research and Treatment. ,vol. 108, pp. 297- 305 ,(2008) , 10.1007/S10549-007-9601-0
E Remák, L Brazil, Cost of managing women presenting with stage IV breast cancer in the United Kingdom. British Journal of Cancer. ,vol. 91, pp. 77- 83 ,(2004) , 10.1038/SJ.BJC.6601890